Israel-based clinical-stage company Purple Biotech (Nasdaq: PPBT) saw its shares edge up more than 4% to 53.10 shekels today, when it announced

CathWorks announced today that the first patient has been enrolled in the Advancing Cath

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced positive data from its Phase I/II study to evaluate the safety and efficacy of MW005 in the treatment of low-risk Basal Cell Carcinoma (BCC). The data show MW005 to be safe and well-tolerated, with patients achieving complete clinical and histological clearance of their target lesions.

Israel-based clinical-stage company Purple Biotech (Nasdaq: PPBT) saw its shares edge up more than 4% to 53.10 shekels today, when it announced

CathWorks announced today that the first patient has been enrolled in the Advancing Cath

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced positive data from its Phase I/II study to evaluate the safety and efficacy of MW005 in the treatment of low-risk Basal Cell Carcinoma (BCC). The data show MW005 to be safe and well-tolerated, with patients achieving complete clinical and histological clearance of their target lesions.

Israel-based clinical-stage company Purple Biotech (Nasdaq: PPBT) saw its shares edge up more than 4% to 53.10 shekels today, when it announced

CathWorks announced today that the first patient has been enrolled in the Advancing Cath

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced positive data from its Phase I/II study to evaluate the safety and efficacy of MW005 in the treatment of low-risk Basal Cell Carcinoma (BCC). The data show MW005 to be safe and well-tolerated, with patients achieving complete clinical and histological clearance of their target lesions.